Literature DB >> 31594793

Neovascularisation in tendinopathy: from eradication to stabilisation?

Tero Ah Järvinen1.   

Abstract

Entities:  

Keywords:  Overuse injury; Sports medicine; Tendinopathy; Tendinosis; Tendon

Mesh:

Year:  2019        PMID: 31594793      PMCID: PMC6923943          DOI: 10.1136/bjsports-2019-100608

Source DB:  PubMed          Journal:  Br J Sports Med        ISSN: 0306-3674            Impact factor:   13.800


× No keyword cloud information.
Tendinopathy is the most common disorder in sports medicine. Multiple hypotheses have been proposed for the aetiopathogenesis, but many aspects still remain elusive. Microdialysis studies have shown high levels of lactate within tendinosis, even at resting tendons,1 suggesting that hypoxia persists in tendinopathy. The presence of necrotic tenocytes, blocked arteries and anaerobic enzymes within tendinopathy lesions lend further support to the role of hypoxia in the aetiopathogenesis.2 Finally, ‘tendinosis’, the pathognomonic histopathological finding in tendinopathy, is composed of hypoxic, mucoid, hyaline and fibrinoid tissue.2 These tissue types are known to be hypoxia induced. Tendons are generally poorly vascularised, while certain regions—those most prone to injury—are almost avascular. This can be considered an evolutionary ‘design failure’ that makes tendons susceptible to chronic and acute injuries. As a consequence, healthy tendons have a virtually non-existent tissue turnover throughout adulthood.3 However, somewhat paradoxically, tissue turnover is increased in tendinopathic tendons.3 Given the persisting hypoxia and subsequent anaerobic metabolism,1 2 it comes as no surprise that the enhanced tissue turnover leads to production of poorly organised tissue—tendinosis—in tendinopathy.2 The fundamental survival mechanism of any cell under hypoxia is the activation of hypoxia-inducible factor-1α (HIF-1α),4 a transcription factor that turns on the expression of a large range of genes encoding angiogenic growth factors. 4 5 Characteristic features of both tendinopathic and ruptured tendons are elevated expression of HIF-1α and its target genes, the proangiogenic growth factors, such as vascular endothelial growth factor and abundant neovascularisation.(figure 1).5 The neovascularisation has even been proposed as the origin of tendinopathy-related pain,6 and accordingly, its eradication has been used as a therapy for the condition.6 Given that tissue regeneration requires sufficient supply of oxygen and nutrients, the existence of neovascularisation in tendinopathy should be interpreted as a sign of both persisting hypoxia and failed tissue repair attempt.
Figure 1

Stabilisation of neovessels in tendinopathy. (A) Tendons respond to hypoxia by secreting angiogenic growth factors that induce the growth of neovessels in tendinopathy. (B) These neovessels are hyperpermeable2; they leak and do not have proper perfusion, failing to deliver oxygen and nutrients required for tissue regeneration. Fibrin-rich exudates leak from the neovessels, which results in fibrinoid degeneration, a typical feature of tendinosis in tendinopathy.2 (C) Future therapies should aim to ‘stabilise’ the neovessels, re-establishing the structural integrity of the vessel walls (lumenisation) and consequently enabling proper perfusion that replenishes supply of oxygen and nutrients. Picture adapted with permission from Taylor and Francis Group.9

Stabilisation of neovessels in tendinopathy. (A) Tendons respond to hypoxia by secreting angiogenic growth factors that induce the growth of neovessels in tendinopathy. (B) These neovessels are hyperpermeable2; they leak and do not have proper perfusion, failing to deliver oxygen and nutrients required for tissue regeneration. Fibrin-rich exudates leak from the neovessels, which results in fibrinoid degeneration, a typical feature of tendinosis in tendinopathy.2 (C) Future therapies should aim to ‘stabilise’ the neovessels, re-establishing the structural integrity of the vessel walls (lumenisation) and consequently enabling proper perfusion that replenishes supply of oxygen and nutrients. Picture adapted with permission from Taylor and Francis Group.9 Although almost completely ignored in sports medicine, it is well-established in the fields of cancer biology and retinopathy that hypoxia-induced neovessels are hyperpermeable.4 In essence, they leak and do not have proper perfusion4 (figure 1). These hyperpermeable neovessels fail to deliver oxygen and nutrients required for tissue maintenance and possible regeneration. Hyperpermeability also explains the apparent intellectual paradox as to why there is persisting hypoxia within regions of neovascularity.4 As noted, there are some preliminary data to suggest that eradication of neovascularisation has some efficacy in the treatment of tendinopathy. However, from a biological perspective, it is somewhat counterintuitive to assume that eradication of neovessels—those originally induced by cells struggling to survive under hypoxic conditions—could offer a viable long-term solution for tendinopathy. At least, in cancer and retinopathy—conditions with similar vascular changes—antiangiogenic therapies have merely worsened the underlying ischaemia.4 7 A tempting alternative approach is to ‘normalise’ or ‘stabilise’ the neovessels4 (figure 1). These ‘stabilised’ blood vessels with structurally intact vessel walls (lumenisation) and proper perfusion could replenish the supply of oxygen and nutrients and, consequently, enable proper tendon regeneration4 7 (figure 1). Although normalisation of neovascularisations may sound like science fiction, recent discoveries in vascular biology offer new hope, as genes responsible for the stabilisation of neovessels have been identified recently.7 Among them, R-Ras is a small GTPase with a pivotal role in maintaining both proper vascular stabilisation and blood vessel lumenisation.7 It also supports endothelial cell survival.7 Lack of R-Ras, in turn, is associated with hyperpermeable neovessels in neovascular human diseases such as retinopathy and cancer and leads to improper lumenisation of blood vessels in ischaemic skeletal muscle.7 The re-introduction of R-Ras, in turn, stabilised the non-functional blood vessels, restoring proper lumen formation and perfusion and, most importantly, reversing hypoxia.7 The proposed hypoxia-induced pathogenesis for tendinopathy might seem at odds with Doppler ultrasound studies that have shown normal oxygen saturation in tendinopathic tendons.8 However, arterio-venous anastomoses are common in diseased tendons, providing a bypass route for circulation and thus a plausible explanation for the failure to detect reduced oxygen saturation in tendinopathic tendons.2 In the end, hypoxia is the only possible explanation for the reported high levels of lactate1 and particularly for the characteristic histopathological findings in tendinopathic tendons.2 The quest for new therapies in sports medicine should rely on the discoveries of basic science. The novel model presented proposes a pivotal role for hypoxia in the aetiopathogenesis of tendinopathy. Tendons respond to hypoxia by secreting angiogenic growth factors to induce the growth of neovessels (figure 1). Unfortunately, these neovessels are non-functional by nature, failing to deliver oxygen and nutrients required to reverse the prevailing hypoxia. Stabilisation of neovessels could offer a tempting future therapeutic approach for the treatment of tendinopathy.
  9 in total

1.  Midportion achilles tendon microcirculation after intermittent combined cryotherapy and compression compared with cryotherapy alone: a randomized trial.

Authors:  Karsten Knobloch; Ruth Grasemann; Marcus Spies; Peter M Vogt
Journal:  Am J Sports Med       Date:  2008-07-18       Impact factor: 6.202

Review 2.  The role of vasculature and angiogenesis for the pathogenesis of degenerative tendons disease.

Authors:  T Pufe; W J Petersen; R Mentlein; B N Tillmann
Journal:  Scand J Med Sci Sports       Date:  2005-08       Impact factor: 4.221

Review 3.  Rescue plan for Achilles: Therapeutics steering the fate and functions of stem cells in tendon wound healing.

Authors:  Magdalena Schneider; Peter Angele; Tero A H Järvinen; Denitsa Docheva
Journal:  Adv Drug Deliv Rev       Date:  2017-12-24       Impact factor: 15.470

4.  Carbon-14 bomb pulse dating shows that tendinopathy is preceded by years of abnormally high collagen turnover.

Authors:  Katja Maria Heinemeier; Peter Schjerling; Tommy F Øhlenschlæger; Christian Eismark; Jesper Olsen; Michael Kjær
Journal:  FASEB J       Date:  2018-03-23       Impact factor: 5.191

5.  Histopathological findings in chronic tendon disorders.

Authors:  M Järvinen; L Józsa; P Kannus; T L Järvinen; M Kvist; W Leadbetter
Journal:  Scand J Med Sci Sports       Date:  1997-04       Impact factor: 4.221

6.  High intratendinous lactate levels in painful chronic Achilles tendinosis. An investigation using microdialysis technique.

Authors:  Håkan Alfredson; Dennis Bjur; Kim Thorsen; Ronny Lorentzon; Patrick Sandström
Journal:  J Orthop Res       Date:  2002-09       Impact factor: 3.494

Review 7.  Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality.

Authors:  Alan McIntyre; Adrian L Harris
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

8.  R-Ras-Akt axis induces endothelial lumenogenesis and regulates the patency of regenerating vasculature.

Authors:  Fangfei Li; Junko Sawada; Masanobu Komatsu
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 14.919

9.  Normalization of tumor vasculature by R-Ras.

Authors:  Junko Sawada; Masanobu Komatsu
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

  9 in total
  14 in total

1.  Effects of isometric loading intensity on patellar tendon microvascular response.

Authors:  Jacob E Earp; Haley Gesick; Domenic Angelino; Alessandra Adami
Journal:  Scand J Med Sci Sports       Date:  2022-05-08       Impact factor: 4.645

2.  [Tendinopathies of the Achilles tendon].

Authors:  Anja Hirschmüller; Oliver Morath
Journal:  Z Rheumatol       Date:  2021-07-21       Impact factor: 1.372

Review 3.  The analgesic effect of joint mobilization and manipulation in tendinopathy: a narrative review.

Authors:  Christos Savva; Christos Karagiannis; Vasileios Korakakis; Michalis Efstathiou
Journal:  J Man Manip Ther       Date:  2021-03-26

Review 4.  Exploration of Oxygen-Induced Retinopathy Model to Discover New Therapeutic Drug Targets in Retinopathies.

Authors:  Maria Vähätupa; Tero A H Järvinen; Hannele Uusitalo-Järvinen
Journal:  Front Pharmacol       Date:  2020-06-11       Impact factor: 5.810

Review 5.  Systemically Administered, Target-Specific, Multi-Functional Therapeutic Recombinant Proteins in Regenerative Medicine.

Authors:  Tero A H Järvinen; Toini Pemmari
Journal:  Nanomaterials (Basel)       Date:  2020-01-28       Impact factor: 5.076

Review 6.  Spectrum of Tendon Pathologies: Triggers, Trails and End-State.

Authors:  Sara Steinmann; Christian G Pfeifer; Christoph Brochhausen; Denitsa Docheva
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

7.  Doppler Flow Response Following Running Exercise Differs Between Healthy and Tendinopathic Achilles Tendons.

Authors:  Lucie Risch; Frank Mayer; Michael Cassel
Journal:  Front Physiol       Date:  2021-03-23       Impact factor: 4.566

Review 8.  The Bonar Score in the Histopathological Assessment of Tendinopathy and Its Clinical Relevance-A Systematic Review.

Authors:  Maria Zabrzyńska; Dariusz Grzanka; Wioletta Zielińska; Łukasz Jaworski; Przemysław Pękala; Maciej Gagat
Journal:  Medicina (Kaunas)       Date:  2021-04-09       Impact factor: 2.430

9.  Platelet-rich plasma injection for tennis elbow: did it ever work?

Authors:  Teemu Karjalainen; Bethan Richards; Rachelle Buchbinder
Journal:  BMJ Open Sport Exerc Med       Date:  2022-01-11

10.  Intraindividual Doppler Flow Response to Exercise Differs Between Symptomatic and Asymptomatic Achilles Tendons.

Authors:  Lucie Risch; Josefine Stoll; Anne Schomöller; Tilman Engel; Frank Mayer; Michael Cassel
Journal:  Front Physiol       Date:  2021-07-06       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.